Cargando…

Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation

PURPOSE: Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on recipient outcomes and graft alloimmune function is uncertain. PATIENTS AND METHODS: We p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibson, Christopher J., Kim, Haesook T., Zhao, Lin, Murdock, H. Moses, Hambley, Bryan, Ogata, Alana, Madero-Marroquin, Rafael, Wang, Shiyu, Green, Lisa, Fleharty, Mark, Dougan, Tyler, Cheng, Chi-An, Blumenstiel, Brendan, Cibulskis, Carrie, Tsuji, Junko, Duran, Madeleine, Gocke, Christopher D., Antin, Joseph H., Nikiforow, Sarah, DeZern, Amy E., Chen, Yi-Bin, Ho, Vincent T., Jones, Richard J., Lennon, Niall J., Walt, David R., Ritz, Jerome, Soiffer, Robert J., Gondek, Lukasz P., Lindsley, R. Coleman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718176/ https://www.ncbi.nlm.nih.gov/pubmed/34793200 http://dx.doi.org/10.1200/JCO.21.02286

Ejemplares similares

Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation
por: Gondek, Lukasz P., et al.
Publicado: (2016)

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
por: Kim, Haesook T., et al.
Publicado: (2022)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
por: Nauffal, Mary, et al.
Publicado: (2022)

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
por: Shapiro, Roman M., et al.
Publicado: (2023)

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation
por: Kekre, Natasha, et al.
Publicado: (2017)

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
por: Maurer, Katie, et al.
Publicado: (2023)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation
por: Kim, Haesook T., et al.
Publicado: (2021)

IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults
por: Politikos, Ioannis, et al.
Publicado: (2015)

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
por: Whangbo, Jennifer S., et al.
Publicado: (2022)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features
por: Sidhom, John-William, et al.
Publicado: (2021)

Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes
por: Pasca, Sergiu, et al.
Publicado: (2023)

Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT
por: Li, L, et al.
Publicado: (2014)

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation
por: Rambaldi, Benedetta, et al.
Publicado: (2022)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
por: Maurer, Katie, et al.
Publicado: (2021)

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2022)

Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome
por: Brown, Jennifer R., et al.
Publicado: (2012)

Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation
por: Zorn, Emmanuel, et al.
Publicado: (2004)

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results
por: Koreth, John, et al.
Publicado: (2018)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

Editorial: Advancing Science for Clinical Care in MDS
por: Figueroa, Maria E., et al.
Publicado: (2022)

Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience
por: Maurer, Katie, et al.
Publicado: (2021)

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
por: Shapiro, Roman M., et al.
Publicado: (2022)

Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease
por: Gondek, Lukasz P., et al.
Publicado: (2022)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology
por: Karantanos, Theodoros, et al.
Publicado: (2021)

Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes
por: Tsai, Harrison K., et al.
Publicado: (2022)

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
por: Mouhieddine, Tarek H., et al.
Publicado: (2020)

Are We Ready For “Triplet” Therapy in Higher-Risk MDS?
por: Brunner, Andrew M., et al.
Publicado: (2023)

Normal and Neoplastic Hematopoiesis
por: Morin, Michael J.
Publicado: (1984)

Randomized Study of enterade(®) to Reduce Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
por: De Filipp, Zachariah, et al.
Publicado: (2021)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
por: Karantanos, Theodoros, et al.
Publicado: (2022)

Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation
por: Karantanos, Theodoros, et al.
Publicado: (2019)

Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant?
por: Abel, Gregory A., et al.
Publicado: (2020)

Multicenter Validation Study of a Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes
por: Armand, Philippe, et al.
Publicado: (2009)

Clonal Hematopoiesis Before, During, and After Human Spaceflight
por: Mencia-Trinchant, Nuria, et al.
Publicado: (2020)

FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
por: Li, Andrew Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7qcle1kl9qe6kpd7ks30bs9fj1